Chengdu Novo-Shengtai Biotechnology

Chengdu Novo-Shengtai Biotechnology is a biopharmaceutical company focused on the research, development, and industrialization of innovative peptide drugs and complex formulations. Located in Chengdu, China, the company leverages proprietary platforms for long-acting peptide modification and oral drug delivery to target metabolic diseases such as diabetes and obesity. Its portfolio includes a range of GLP-1 receptor agonists and multi-target peptide candidates designed to improve patient compliance and therapeutic outcomes. The firm operates a comprehensive R&D center and GMP-compliant manufacturing facilities to support its clinical pipeline. By integrating advanced chemical synthesis with biological engineering, the company aims to provide more accessible and effective treatment options for chronic metabolic conditions.